{"id":47760,"date":"2022-08-29T17:01:55","date_gmt":"2022-08-29T15:01:55","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/fatty-acid-amide-hydrolase-faah-inhibitor-pipeline-insight-2022-researchandmarkets-com\/"},"modified":"2022-08-29T17:01:55","modified_gmt":"2022-08-29T15:01:55","slug":"fatty-acid-amide-hydrolase-faah-inhibitor-pipeline-insight-2022-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/fatty-acid-amide-hydrolase-faah-inhibitor-pipeline-insight-2022-researchandmarkets-com\/","title":{"rendered":"Fatty Acid Amide Hydrolase (FAAH) Inhibitor Pipeline Insight 2022 &#8211; ResearchAndMarkets.com"},"content":{"rendered":"<div>\n<p>DUBLIN&#8211;(BUSINESS WIRE)&#8211;The <a target=\"_blank\" href=\"https:\/\/www.researchandmarkets.com\/reports\/4382597\/fatty-acid-amide-hydrolase-faah-inhibitor?utm_source=BW&amp;utm_medium=PressRelease&amp;utm_code=z5fxrw&amp;utm_campaign=1743222+-+Fatty+Acid+Amide+Hydrolase+(FAAH)+Inhibitor+Pipeline+Insight+2022&amp;utm_exec=como322prd\" rel=\"nofollow noopener\" shape=\"rect\">&#8220;Fatty Acid Amide Hydrolase (FAAH) Inhibitor &#8211; Pipeline Insight, 2022&#8221;<\/a> clinical trials has been added to <strong>ResearchAndMarkets.com&#8217;s<\/strong> offering.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20220829005537\/en\/1555542\/4\/logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20220829005537\/en\/1555542\/21\/logo.jpg\"><\/a><\/p>\n<p>\n&#8220;Fatty Acid Amide Hydrolase (FAAH) Inhibitor &#8211; Pipeline Insight, 2022&#8221; report by the publisher offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Fatty Acid Amide Hydrolase (FAAH) Inhibitor development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.\n<\/p>\n<p>\n<strong>Pipeline Products covered across the following Developmental Stages<\/strong>\n<\/p>\n<ul>\n<li>\nClinical\n<\/li>\n<li>\nNon-clinical\n<\/li>\n<\/ul>\n<p>\n<strong>Descriptive coverage of pipeline development activities for Fatty Acid Amide Hydrolase (FAAH) Inhibitor<\/strong>\n<\/p>\n<p>\nPipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&amp;D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.\n<\/p>\n<p>\n<strong>Pipeline Therapeutics assessment of products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor<\/strong>\n<\/p>\n<p>\nThe report assesses the active Fatty Acid Amide Hydrolase (FAAH) Inhibitor pipeline products by developmental stage, product type, molecule type, and administration route.\n<\/p>\n<p>\n<strong>Methodology<\/strong>\n<\/p>\n<p>\nData used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by the publisher&#8217;s team of industry experts.\n<\/p>\n<p>\nInformation and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.\n<\/p>\n<p>\n<strong>Scope of the Report<\/strong>\n<\/p>\n<ul>\n<li>\nProvides a snapshot of the therapeutics pipeline activity for Fatty Acid Amide Hydrolase (FAAH) Inhibitor\n<\/li>\n<li>\nFeatures the Fatty Acid Amide Hydrolase (FAAH) Inhibitor pipeline across the complete product development cycle including all clinical and non-clinical stages\n<\/li>\n<li>\nOffers detailed therapeutic product profiles of Fatty Acid Amide Hydrolase (FAAH) Inhibitor with key coverage of developmental activities including licensing &amp; collaboration deals, patent details, designations, technologies, indications and chemical information\n<\/li>\n<li>\nTherapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration\n<\/li>\n<li>\nCoverage of dormant and discontinued pipeline projects across Fatty Acid Amide Hydrolase (FAAH) Inhibitor\n<\/li>\n<\/ul>\n<p>\n<strong>Reasons to Buy<\/strong>\n<\/p>\n<ul>\n<li>\nEstablish a comprehensive understanding of the current pipeline scenario across Fatty Acid Amide Hydrolase (FAAH) Inhibitor to formulate effective R&amp;D strategies\n<\/li>\n<li>\nAssess challenges and opportunities that influence Fatty Acid Amide Hydrolase (FAAH) Inhibitor research &amp; development (R&amp;D)\n<\/li>\n<li>\nGather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage\n<\/li>\n<li>\nIdentify and understand the sought after therapy areas and indications for Fatty Acid Amide Hydrolase (FAAH) Inhibitor\n<\/li>\n<li>\nIdentify the product attributes and use it for target finding, drug repurposing, and precision medicine\n<\/li>\n<li>\nDevise in licensing and out licensing strategies by identifying prospective partners with progressing projects for Fatty Acid Amide Hydrolase (FAAH) Inhibitor to enhance and expand business potential and scope\n<\/li>\n<li>\nPlan prospective mergers and acquisitions effectively by identifying key players in this area and their most promising pipeline therapeutics and developmental progress\n<\/li>\n<li>\nThe extensive domain knowledge on therapy areas supports the client in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugs\n<\/li>\n<\/ul>\n<p>\n<strong>Key Topics Covered:<\/strong>\n<\/p>\n<p>\n<strong>1. Report Introduction<\/strong>\n<\/p>\n<p>\n<strong>2. Fatty Acid Amide Hydrolase (FAAH) Inhibitor &#8211; Overview<\/strong>\n<\/p>\n<p>\n<strong>3. Pipeline Therapeutics<\/strong>\n<\/p>\n<ul>\n<li>\nAn Overview of Pipeline Products for Fatty Acid Amide Hydrolase (FAAH) Inhibitor\n<\/li>\n<\/ul>\n<p>\n<strong>4. Comparative Analysis<\/strong>\n<\/p>\n<p>\n<strong>5. Fatty Acid Amide Hydrolase (FAAH) Inhibitor Pipeline Products in Clinical Stages<\/strong>\n<\/p>\n<p>\n5.1 Drug Name: Company Name\n<\/p>\n<ul>\n<li>\nProduct Description\n<\/li>\n<li>\nResearch and Development\n<\/li>\n<li>\nProduct Development Activities\n<\/li>\n<\/ul>\n<p>\n<strong>6. Fatty Acid Amide Hydrolase (FAAH) Inhibitor Pipeline Products in Non-clinical Stages<\/strong>\n<\/p>\n<p>\n6.1 Drug Name: Company Name\n<\/p>\n<ul>\n<li>\nProduct Description\n<\/li>\n<li>\nResearch and Development\n<\/li>\n<li>\nProduct Development Activities\n<\/li>\n<\/ul>\n<p>\n<strong>7. Therapeutic Assessment: Active Products<\/strong>\n<\/p>\n<ul>\n<li>\nPipeline Assessment by Route of Administration\n<\/li>\n<li>\nPipeline Assessment by Stage and Route of Administration\n<\/li>\n<li>\nPipeline Assessment by Molecule Type\n<\/li>\n<li>\nPipeline Assessment by Stage and Molecule Type\n<\/li>\n<\/ul>\n<p>\n<strong>8. Inactive Pipeline Products<\/strong>\n<\/p>\n<p>\n8.1 Drug Name: Company Name\n<\/p>\n<ul>\n<li>\nProduct Description\n<\/li>\n<li>\nResearch and Development\n<\/li>\n<li>\nProduct Development Activities\n<\/li>\n<li>\nReason for dormancy\/discontinuation\n<\/li>\n<\/ul>\n<p>\n<strong>Appendix<\/strong>\n<\/p>\n<p>\n<strong>Report Methodology<\/strong>\n<\/p>\n<p>\n<strong>Consulting Services<\/strong>\n<\/p>\n<p>\n<strong>Disclaimer<\/strong>\n<\/p>\n<p>\n<strong>About the Publisher<\/strong>\n<\/p>\n<p>\n<strong>Companies Mentioned<\/strong>\n<\/p>\n<ul>\n<li>\nJohnson &amp; Johnson\n<\/li>\n<li>\nRenovis\n<\/li>\n<li>\nVernalis\n<\/li>\n<li>\nPfizer\n<\/li>\n<li>\nMayssen-Cilag\n<\/li>\n<li>\nsanofi-aventis\n<\/li>\n<li>\nAdvinus Therapeutics\n<\/li>\n<\/ul>\n<p>\nFor more information about this clinical trials report visit <a target=\"_blank\" href=\"https:\/\/www.researchandmarkets.com\/reports\/4382597\/fatty-acid-amide-hydrolase-faah-inhibitor?utm_source=BW&amp;utm_medium=PressRelease&amp;utm_code=z5fxrw&amp;utm_campaign=1743222+-+Fatty+Acid+Amide+Hydrolase+(FAAH)+Inhibitor+Pipeline+Insight+2022&amp;utm_exec=como322prd\" rel=\"nofollow noopener\" shape=\"rect\">https:\/\/www.researchandmarkets.com\/r\/xpvt9x<\/a>\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nResearchAndMarkets.com<br \/>\n<br \/>Laura Wood, Senior Press Manager<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#x61;&#x69;l&#116;&#x6f;&#x3a;p&#114;&#x65;s&#115;&#x40;&#x72;e&#115;&#x65;a&#114;&#x63;&#x68;a&#110;&#x64;&#x6d;&#97;&#x72;&#x6b;e&#116;&#x73;&#x2e;c&#111;&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">&#112;r&#101;s&#115;&#64;&#x72;e&#x73;e&#x61;r&#x63;h&#x61;n&#x64;m&#x61;r&#x6b;e&#x74;s&#x2e;&#99;&#x6f;&#109;<\/a>\n<\/p>\n<p>\nFor E.S.T Office Hours Call 1-917-300-0470<br \/>\n<br \/>For U.S.\/CAN Toll Free Call 1-800-526-8630<br \/>\n<br \/>For GMT Office Hours Call +353-1-416-8900\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Fatty Acid Amide Hydrolase (FAAH) Inhibitor &#8211; Pipeline Insight, 2022&#8221; clinical trials has been added to ResearchAndMarkets.com&#8217;s offering. &#8220;Fatty Acid Amide Hydrolase (FAAH) Inhibitor &#8211; Pipeline Insight, 2022&#8221; report by the publisher offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Fatty Acid Amide Hydrolase (FAAH) Inhibitor development. &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/fatty-acid-amide-hydrolase-faah-inhibitor-pipeline-insight-2022-researchandmarkets-com\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-47760","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Fatty Acid Amide Hydrolase (FAAH) Inhibitor Pipeline Insight 2022 - ResearchAndMarkets.com - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/fatty-acid-amide-hydrolase-faah-inhibitor-pipeline-insight-2022-researchandmarkets-com\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Fatty Acid Amide Hydrolase (FAAH) Inhibitor Pipeline Insight 2022 - ResearchAndMarkets.com - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Fatty Acid Amide Hydrolase (FAAH) Inhibitor &#8211; Pipeline Insight, 2022&#8221; clinical trials has been added to ResearchAndMarkets.com&#8217;s offering. &#8220;Fatty Acid Amide Hydrolase (FAAH) Inhibitor &#8211; Pipeline Insight, 2022&#8221; report by the publisher offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Fatty Acid Amide Hydrolase (FAAH) Inhibitor development. ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/fatty-acid-amide-hydrolase-faah-inhibitor-pipeline-insight-2022-researchandmarkets-com\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-08-29T15:01:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220829005537\/en\/1555542\/21\/logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fatty-acid-amide-hydrolase-faah-inhibitor-pipeline-insight-2022-researchandmarkets-com\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fatty-acid-amide-hydrolase-faah-inhibitor-pipeline-insight-2022-researchandmarkets-com\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Fatty Acid Amide Hydrolase (FAAH) Inhibitor Pipeline Insight 2022 &#8211; ResearchAndMarkets.com\",\"datePublished\":\"2022-08-29T15:01:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fatty-acid-amide-hydrolase-faah-inhibitor-pipeline-insight-2022-researchandmarkets-com\\\/\"},\"wordCount\":747,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fatty-acid-amide-hydrolase-faah-inhibitor-pipeline-insight-2022-researchandmarkets-com\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220829005537\\\/en\\\/1555542\\\/21\\\/logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fatty-acid-amide-hydrolase-faah-inhibitor-pipeline-insight-2022-researchandmarkets-com\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fatty-acid-amide-hydrolase-faah-inhibitor-pipeline-insight-2022-researchandmarkets-com\\\/\",\"name\":\"Fatty Acid Amide Hydrolase (FAAH) Inhibitor Pipeline Insight 2022 - ResearchAndMarkets.com - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fatty-acid-amide-hydrolase-faah-inhibitor-pipeline-insight-2022-researchandmarkets-com\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fatty-acid-amide-hydrolase-faah-inhibitor-pipeline-insight-2022-researchandmarkets-com\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220829005537\\\/en\\\/1555542\\\/21\\\/logo.jpg\",\"datePublished\":\"2022-08-29T15:01:55+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fatty-acid-amide-hydrolase-faah-inhibitor-pipeline-insight-2022-researchandmarkets-com\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fatty-acid-amide-hydrolase-faah-inhibitor-pipeline-insight-2022-researchandmarkets-com\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fatty-acid-amide-hydrolase-faah-inhibitor-pipeline-insight-2022-researchandmarkets-com\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220829005537\\\/en\\\/1555542\\\/21\\\/logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220829005537\\\/en\\\/1555542\\\/21\\\/logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fatty-acid-amide-hydrolase-faah-inhibitor-pipeline-insight-2022-researchandmarkets-com\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Fatty Acid Amide Hydrolase (FAAH) Inhibitor Pipeline Insight 2022 &#8211; ResearchAndMarkets.com\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Fatty Acid Amide Hydrolase (FAAH) Inhibitor Pipeline Insight 2022 - ResearchAndMarkets.com - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/fatty-acid-amide-hydrolase-faah-inhibitor-pipeline-insight-2022-researchandmarkets-com\/","og_locale":"en_US","og_type":"article","og_title":"Fatty Acid Amide Hydrolase (FAAH) Inhibitor Pipeline Insight 2022 - ResearchAndMarkets.com - Pharma Trend","og_description":"DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Fatty Acid Amide Hydrolase (FAAH) Inhibitor &#8211; Pipeline Insight, 2022&#8221; clinical trials has been added to ResearchAndMarkets.com&#8217;s offering. &#8220;Fatty Acid Amide Hydrolase (FAAH) Inhibitor &#8211; Pipeline Insight, 2022&#8221; report by the publisher offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Fatty Acid Amide Hydrolase (FAAH) Inhibitor development. ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/fatty-acid-amide-hydrolase-faah-inhibitor-pipeline-insight-2022-researchandmarkets-com\/","og_site_name":"Pharma Trend","article_published_time":"2022-08-29T15:01:55+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220829005537\/en\/1555542\/21\/logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/fatty-acid-amide-hydrolase-faah-inhibitor-pipeline-insight-2022-researchandmarkets-com\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/fatty-acid-amide-hydrolase-faah-inhibitor-pipeline-insight-2022-researchandmarkets-com\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Fatty Acid Amide Hydrolase (FAAH) Inhibitor Pipeline Insight 2022 &#8211; ResearchAndMarkets.com","datePublished":"2022-08-29T15:01:55+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/fatty-acid-amide-hydrolase-faah-inhibitor-pipeline-insight-2022-researchandmarkets-com\/"},"wordCount":747,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/fatty-acid-amide-hydrolase-faah-inhibitor-pipeline-insight-2022-researchandmarkets-com\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220829005537\/en\/1555542\/21\/logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/fatty-acid-amide-hydrolase-faah-inhibitor-pipeline-insight-2022-researchandmarkets-com\/","url":"https:\/\/pharma-trend.com\/en\/fatty-acid-amide-hydrolase-faah-inhibitor-pipeline-insight-2022-researchandmarkets-com\/","name":"Fatty Acid Amide Hydrolase (FAAH) Inhibitor Pipeline Insight 2022 - ResearchAndMarkets.com - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/fatty-acid-amide-hydrolase-faah-inhibitor-pipeline-insight-2022-researchandmarkets-com\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/fatty-acid-amide-hydrolase-faah-inhibitor-pipeline-insight-2022-researchandmarkets-com\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220829005537\/en\/1555542\/21\/logo.jpg","datePublished":"2022-08-29T15:01:55+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/fatty-acid-amide-hydrolase-faah-inhibitor-pipeline-insight-2022-researchandmarkets-com\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/fatty-acid-amide-hydrolase-faah-inhibitor-pipeline-insight-2022-researchandmarkets-com\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/fatty-acid-amide-hydrolase-faah-inhibitor-pipeline-insight-2022-researchandmarkets-com\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220829005537\/en\/1555542\/21\/logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220829005537\/en\/1555542\/21\/logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/fatty-acid-amide-hydrolase-faah-inhibitor-pipeline-insight-2022-researchandmarkets-com\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Fatty Acid Amide Hydrolase (FAAH) Inhibitor Pipeline Insight 2022 &#8211; ResearchAndMarkets.com"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47760","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=47760"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47760\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=47760"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=47760"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=47760"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}